Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia

Blood Cells, Molecules, and Diseases

Volumn 47, Issue 4, 2011, Pages 232-234

  Musallam, Khaled M ^a   Taher, Ali T ^a   Duca, Lorena ^b   Cesaretti, Claudia ^b   Halawi, Racha ^a   Cappellini, Maria Domenica ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Clinical complications; Growth differentiation factor 15; Ineffective erythropoiesis; Iron overload; Thalassemia intermedia

Indexed keywords

FERRITIN; GROWTH DIFFERENTIATION FACTOR 15; HEMOGLOBIN;

ACQUIRED HEMOLYTIC ANEMIA; ADULT; AGED; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SEX DIFFERENCE; SPLENECTOMY; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; AGED; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 82955187600     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.07.005     Document Type: Article

References (18)

1. Steinberg M.H., Forget B.G., Higgs D.R., Weatherall D.J. Disorders of hemoglobin: genetics pathophysiology, and clinical management 2009, Cambridge University Press, Cambridge.
2. Taher A.T., Musallam K.M., Cappellini M.D., Weatherall D.J. Optimal management of beta thalassaemia intermedia. Br. J. Haematol. 2011, 152:512-523.
3. Taher A.T., Musallam K.M., El-Beshlawy A., et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br. J. Haematol. 2010, 150:486-489.
4. Taher A.T., Musallam K.M., Karimi M., et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010, 115:1886-1892.
5. Origa R., Galanello R., Ganz T., et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica 2007, 92:583-588.
6. Taher A., Isma'eel H., Cappellini M.D. Thalassemia intermedia: revisited. Blood Cells Mol. Dis. 2006, 37:12-20.
7. Tanno T., Noel P., Miller J.L. Growth differentiation factor 15 in erythroid health and disease. Curr. Opin. Hematol. 2010, 17:184-190.
8. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 2007, 13:1096-1101.
9. St Pierre T.G., Clark P.R., Chua-anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105:855-861.
10. Wood J.C., Enriquez C., Ghugre N., et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
11. Wood J.C. Magnetic resonance imaging measurement of iron overload. Curr. Opin. Hematol. 2007, 14:183-190.
12. Taher A., Hershko C., Cappellini M.D. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br. J. Haematol. 2009, 147:634-640.
13. Taher A., Musallam K.M., El Rassi F., et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br. J. Haematol. 2009, 146:569-572.
14. Taher A., El Rassi F., Isma'eel H., et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008, 93:1584-1586.
15. Haidar R., Musallam K.M., Taher A.T. Bone disease and skeletal complications in patients with beta thalassemia major. Bone 2011, 48:425-432.
16. Eldor A., Rachmilewitz E.A. The hypercoagulable state in thalassemia. Blood 2002, 99:36-43.
17. Taher A., Isma'eel H., Mehio G., et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb. Haemost. 2006, 96:488-491.
18. Sundaram N., Tailor A., Mendelsohn L., et al. High levels of placenta growth factor in sickle cell disease promote pulmonary hypertension. Blood 2010, 116:109-112.